Iovance Biotherapeutics (IOVA) Asset Writedowns and Impairment (2011 - 2026)

Iovance Biotherapeutics (IOVA) has reported Asset Writedowns and Impairment for 5 consecutive years, with -$506000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Asset Writedowns and Impairment fell 8333.33% year-over-year to -$506000.0; the TTM figure through Mar 2026 stood at $12.9 million (up 75.59% YoY), while the FY2025 annual figure was $13.4 million, up 82.24% from the prior year.
• Asset Writedowns and Impairment slipped to -$506000.0 in Q1 2026 per IOVA's latest filing, from $3.7 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $8.3 million in Q2 2025 and bottomed at -$506000.0 in Q1 2026.
• Historically, Asset Writedowns and Impairment has averaged $2.6 million across 4 years, with a median of $857000.0 in 2022.
• Annual changes were most pronounced in 2025 — Asset Writedowns and Impairment plunged 49.64% — and 2026, when it slumped 8333.33%.
• Iovance Biotherapeutics' Asset Writedowns and Impairment stood at $83000.0 in 2022, then surged by 8761.45% to $7.4 million in 2024, then slumped by 49.64% to $3.7 million in 2025, then slumped by 113.66% to -$506000.0 in 2026.
• Business Quant data shows IOVA's Asset Writedowns and Impairment at -$506000.0 in Q1 2026, $3.7 million in Q4 2025, and $1.4 million in Q3 2025.